KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Liabilities: 2009-2025

Historic Total Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $1.6 billion.

  • Biomarin Pharmaceutical's Total Liabilities rose 8.37% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 8.37%. This contributed to the annual value of $1.3 billion for FY2024, which is 29.58% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Total Liabilities of $1.6 billion as of Q3 2025, which was up 9.02% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Total Liabilities peaked at $1.9 billion during Q4 2023, and registered a low of $1.3 billion during Q4 2024.
  • For the 3-year period, Biomarin Pharmaceutical's Total Liabilities averaged around $1.6 billion, with its median value being $1.8 billion (2023).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Total Liabilities increased by 10.80% in 2021 and then fell by 29.58% in 2024.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Total Liabilities stood at $1.7 billion in 2021, then grew by 1.89% to $1.8 billion in 2022, then climbed by 6.67% to $1.9 billion in 2023, then dropped by 29.58% to $1.3 billion in 2024, then rose by 8.37% to $1.6 billion in 2025.
  • Its Total Liabilities was $1.6 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.4 billion in Q1 2025.